Article Sidebar

PDF
Date Published: 12/06/2023
Online Published: 12/06/2023
Abstract Views: 130
Views PDF: 87
Issue
No. 28 (2020)
Section
Article
How to Cite
Duong, M. L., & Tran , N. D. (2023). HPV- DNA TRANSITION RATE AND RELATED FACTORS TO THIS TRANSITION IN HPV INFECTED WOMEN 18-69 YEARS IN CAN THO CITY. Cantho Journal of Medicine and Pharmacy, 28, 92-97. https://tapchi.ctump.edu.vn/index.php/ctump/article/view/1634

HPV- DNA TRANSITION RATE AND RELATED FACTORS TO THIS TRANSITION IN HPV INFECTED WOMEN 18-69 YEARS IN CAN THO CITY

My Linh Duong1,, Ngoc Dung Tran 1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Cervical cancer is a cancer with a high incidence and death rate. The reason is known by HPV infection. Most women infected with HPV will clear themselves from the body. About 5-10% of new high-risk HPV infections develop into cervical cancer. Objectives: The study was designed to determine DNA-HPV transition rates and related factors to DNA-HPV transition in HPV-infected women of 18–69 years of age in Can Tho City from 2013 to 2019. Materials and methods: Both a retrospective and a prospective cohort study were employed to complete the study. Interviews, gynecological examinations and HPV testing 225 women 18-69 years in can tho city, who were used to collect data for the study. The results were recorded and compared with those of HPV in 2013 to assess the development of HPV over time: transition included conversion to HPV positive state when the results changed from negative (2013) to positive (2019). No transition included clearance of HPV when the positive (2013) results turned negative (2019) or the results remained negative or positive after two phases of testing. At the same time, the factors related to the change were analyzed. Results: There were 16% of cases of DNA-HPV conversion to HPV positive state while 66.6% of cases of DNA-HPV clearance of HPV were witnessed; remaining HPV were 67.1%. The following were recognized as factors that are related to the DNA-HPV harmful transition: age (the ≤ 45 age group had 3.3 times higher of transition risk than the > 45 age group (95%CI: 1.1–9.5)); sexual partner change with OR=3.6 (95%CI: 1.1–12.5); sexual partners change from their husbands' side with OR = 3.9 (95%CI: 1.3–11.8); sexually transmitted diseases with OR = 5.0 (95%CI: 1.2–21.2); and gynecological infections with OR = 3.6 (95%CI: 1.2–11.1). Conclusion: 16% of women with DNA-HPV transition developed conversion to HPV positive state, and it was figured out that the changes in sexual habits will increase the risk of this negative transition.

Article Details

Keywords

HPV infected, transition, related factors, cervical cancer

References

1. Bộ môn Phụ Sản, Trường Đại học Y Dược Thành phố Hồ Chí Minh (2017), Tân sinh trong biểu mô cổ tử cung, Bài giảng phụ khoa, Nhà Xuất Bản Y Học, tr. 58 - 85.
2. Cancer Research UK (2018), Cervical cancer statistics, Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics-by-cancer type/cervical-cancer, [Accessed: August 8, 2019].
3. Chyong-Huey Lai, Angel Chao, Chee-Jen Chang et al (2008), Host and viral factors in relation to clearance of human papillomavirus infection: A cohort study in Taiwan, International Journal of Cancer, Volume 123, Issue 7, pp. 1685–1692.
4. Jill E. Koshiol, Jane C. Schroeder, Denise J. Jamieson et al (2006), Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus”, International Journal of Cancer, Vol. 119, 7, pp. 1623–1629.
5. Jonathan S. Berek et al (2019), Intraepithelial disease of the cervix, Vagina and vulva, Berek & Novak’s Gynecology, Sixteenth edition, Chapter 16. pp.381-408.
6. Patti E. Gravitt (2011), The known unknowns of HPV natural history, J Clin Invest.; 121(12), pp. 4593–4599.
7. Penson RT, Lee LJ (2019), Cervical cancer, BMJ Best Practice. Available from: https://bestpractice.bmj.com/topics/en-gb/259. Subscription required.
8. Sellors JW, Sankaranarayanan R (2003), An introdution to Cervical Intraepithelial Neoplasm (CIN), Colposcopy and treatment of cervical intraepithelial Neoplasia, A Beginner’ Manual, Lyon 4, 2, pp. 13-19.
9. Siegel RL, Miller KD, Jemal A (2018), Cancer statistics, CA Cancer J Clin, 68, pp. 7-30.
10. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al (2007), Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update, Int J Cancer 2007: 121, pp. 621–3210.
11. Thomas J. Bader, MD, translated by Nguyen Duy Tai (2011), “Cervical cancer”, Obstetrics and Gynecology: Things to know. 3rd edition, pp.166 - 170.
12. Viens LJ, Henley SJ, Watson M et al (2016), Human papillomavirus-associated cancers - United States, 2008-2012, MMWR Morb Mortal Wkly Rep, 65, pp. 661 - 6.
13. Von Karsa L, Arbyn M, De Vuyst H et al (2015), European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination, Papillomavirus Research, 1, pp. 22-31.
14. World Health Organization (2019), Human papillomavirus (HPV) and cervical cancer: fact sheet. Available from: https://www.who.int/news-room/fact sheets/detail/humanpapillomavirus-(HPV)-and-cervical-cancer, [Accessed: January 24,2019].